Zobrazeno 1 - 10
of 273
pro vyhledávání: '"Victor J. Marder"'
Since publication of the First Edition in 1982, Hemostasis and Thrombosis has established itself as the pre-eminent book in the field of coagulation disorders. No other book is as inclusive in scope, with coverage of the field from the standpoint of
Autor:
Victor J. Marder, Marc Ribó, Peter Mitchell, Kecia L. Courtney, Jeffrey L. Saver, Bernard Yan, Miroslav Brozman
Publikováno v:
Journal of Stroke and Cerebrovascular Diseases. 26:308-320
Background This phase 1/2a, open-label, multicenter, dose-escalation, safety study describes the first evaluation of plasmin as an intracranial thrombolytic treatment for acute ischemic stroke in the middle cerebral artery. The rationale for intrathr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::199f1cca273c101c70d7b23c81de7a26
https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.09.022
https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.09.022
Autor:
Benjamin Kim, Victor J. Marder, Zachary A. Hing, Zuben E. Sauna, Eric J. Broxham, Chava Kimchi-Sarfaty, David Liuwantara, Pamela Kempert, Tal Schiller, Tom E. Howard, Nathan C. Edwards, Vijaya L. Simhadri, Andrew Wu, Evi B. Struble
Publikováno v:
British Journal of Haematology. 165:154-158
Background Although autosomal recessive hematologic disorders are individually rare and difficult to ascertain, studies involving one or more homozygous affected children and their unaffected heterozygous parents have led to expanded understanding of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db8edb9f528cdc47eec8bbee8fe6af4f
https://doi.org/10.1111/bjh.12713
https://doi.org/10.1111/bjh.12713
Autor:
Ellis J. Neufeld, Susan F. Assmann, Joan Cox Gill, Marcela Torres, Catherine S. Manno, Nigel S. Key, Leslie Raffini, Victor J. Marder, Cindy A. Leissinger, Janna M. Journeycake, Cassandra D. Josephson, Rebecca Kruse-Jarres, Barbara A. Konkle, Carolyn M. Bennett, Margaret V. Ragni, Keith R. McCrae, Leonard A. Valentino, Kapil Saxena, Suzanne Granger
Publikováno v:
Thrombosis and Haemostasis. 112:445-458
SummaryThe development of antibodies against infused factor VIII (FVIII) in patients with haemophilia A is a serious complication leading to poorly controlled bleeding and increased morbidity. No treatment has been proven to reduce high titre antibod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51746c62c4078bf482ec1ab849e0fd69
https://doi.org/10.1160/th14-01-0078
https://doi.org/10.1160/th14-01-0078
Publikováno v:
American Journal of Hematology. 90:561-563
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e28491ec7eaeea81e1199fe6e3afeba
https://doi.org/10.1002/ajh.23969
https://doi.org/10.1002/ajh.23969
Autor:
Richard D. Shlansky-Goldberg, Chunqin Deng, Victor J. Marder, J. P. Davis, Kim Hanna, David Fineberg, Anthony J. Comerota
Publikováno v:
Journal of Thrombosis and Haemostasis. 10:985-991
Summary. Background: Current treatment of acute peripheral artery or bypass graft occlusion utilizes catheter-directed thrombolysis of a plasminogen activator (PA). Plasmin is a direct-acting thrombolytic with a striking safety advantage over PA in p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc0b4306f217ce553907b766e2be9268
https://doi.org/10.1111/j.1538-7836.2012.04728.x
https://doi.org/10.1111/j.1538-7836.2012.04728.x
Autor:
Job Harenberg, Victor J. Marder, Martin Wehling, Svetlana Marx, Ola E. Dahl, Christel Weiss, Astrid Schulze
Publikováno v:
Thrombosis and Haemostasis. 108:903-912
SummaryNew oral anticoagulant (NOAC) regimens [dabigatran 150 mg (D150) and 220 mg (D220), rivaroxaban 10 mg (R20), and apixaban 2.5 mg bid (A5)] were effective and safe compared to enoxaparin for the prevention of venous thromboembolism (VTE) follow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e1e4f2ea4958f25f85f421276575475
https://doi.org/10.1160/th12-07-0482
https://doi.org/10.1160/th12-07-0482
Autor:
Shuo Liu, Victor J. Marder, David E. Levy, Annlia Paganini-Hill, Mark Fisher, Shur-Jen Wang, Fan Yang
Publikováno v:
Stroke. 42:3277-3280
Background and Purpose— Ancrod, derived from Malayan pit viper venom, has been tested as ischemic stroke treatment in clinical trials with inconsistent results. We studied the actions of ancrod on fibrinolysis pathways in patient plasma samples and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62310e1015db7808578c4e24a5eb0da0
https://doi.org/10.1161/strokeaha.111.622753
https://doi.org/10.1161/strokeaha.111.622753
Autor:
Reza Jahan, Theresa Gruber, Aleš Blinc, Gregor Tratar, Victor J. Marder, Gary Duckwiler, Doojin Kim, David S Liebeskind, Paul M. Vespa, Sidney Starkman, Fernando Vinuela, Bruce Ovbiagele, Satoshi Tateshima, Jeffrey L. Saver, Nestor R Gonzalez, Mišo Šabovič, Letisha Ali
Publikováno v:
Stroke. 42:2222-2228
Background and Purpose— Plasmin is a direct-acting thrombolytic with a better safety profile than recombinant tissue-type plasminogen activator (rtPA) in animal models. With the application of retrieval devices for managing acute ischemic stroke, e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fadeff2a7c43db4a3dc854bb514df9e4
https://doi.org/10.1161/strokeaha.110.609198
https://doi.org/10.1161/strokeaha.110.609198
Autor:
Victor J. Marder
Publikováno v:
Thrombosis Research. 123:S56-S61
Plasmin is the prototype of a distinct class of "direct-acting" fibrinolytic agents, with biochemical and physiological attributes that are favorable for catheter-delivered thrombolytic therapy. Our studies indicate that plasmin is superior to plasmi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81bdc5c6674dda8eea1894fc528e93b2
https://doi.org/10.1016/s0049-3848(09)70145-8
https://doi.org/10.1016/s0049-3848(09)70145-8